


Tepilamide fumarate

Cat. No.:	HY-109105		
CAS No.:	1208229-58-6		
Molecular Formula:	C ₁₁ H ₁₇ NO ₅		
Molecular Weight:	243.26		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 125 mg/mL (513.85 mM)
 H₂O : 50 mg/mL (205.54 mM; Need ultrasonic)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	4.1108 mL	20.5541 mL	41.1083 mL
	5 mM	0.8222 mL	4.1108 mL	8.2217 mL
	10 mM	0.4111 mL	2.0554 mL	4.1108 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 25 mg/mL (102.77 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Tepilamide fumarate (XP-23829; PPC-06) is an oral fumaric acid ester, acts as a proagent of [Monomethyl fumarate](#) (HY-103252), and is used in the research of moderate to severe chronic plaque psoriasis^[1].

REFERENCES

[1]. Mrowietz U, et al. Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study. J Clin Aesthet Dermatol. 2022 Jan;15(1):53-58.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA